Pharmacodynamics of variable patient compliance: Implications for pharmaceutical value

Advanced Drug Delivery Reviews

Volumn 33, Issue 3, 1998, Pages 207-219

  Urquhart, John ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Compliance; Drug delivery; Forgiveness; Off response; Omeprazole; Pharmaceutical value; Pharmacodynamics; Pharmacoeconomics; Pharmacokinetics; Rebound effects; Variability

Indexed keywords

DRUG DOSAGE; DRUG INTERACTIONS; DRUG PRODUCTS; PHARMACOKINETICS;

PHARMACOECONOMICS; VARIABLE PATIENT COMPLIANCE;

CONTROLLED DRUG DELIVERY;

OMEPRAZOLE; THEOPHYLLINE;

DRUG DELIVERY SYSTEM; HUMAN; PATIENT COMPLIANCE; PHARMACEUTICS; PHARMACODYNAMICS; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW;

EID: 0032494104     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00029-5     Document Type: Review

References (37)

1. O'Connell J.B., Bristow M.R. Economic impact of heart failure in the United States: time for a different approach. J. Heart Lung Transplant. 13:1994;S107-112.
2. Harter J.G., Peck C.C. Chronobiology: suggestions for integrating it into drug development. Ann. NY Acad. Sci. 618:1991;563-571.
3. Urquhart J. The electronic medication event monitor - lessons for pharmacotherapy. Clin. Pharmacokinet. 32:1997;345-356.
4. de Klerk E., van der Linden S., van der Heijden D., Urquhart J. Facilitated analysis of data on drug regimen compliance. Stat. Med. 16:1997;1653-1664.
5. Kastrissios H., Blaschke T.F. Medication compliance as a feature in drug development. Annu. Rev. Pharmacol. Toxicol. 37:1997;451-475.
6. Ferguson J.A., Sundblad K.J., Becker P.K., Gorski J.C., Rudy D.W., Brater D.C. Role of duration of diuretic effect in preventing sodium retention. Clin. Pharmacol. Ther. 62:1997;203-208.
7. Rangno R.E., Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol, and pindolol. Am. Heart J. 104:1982;473-478.
8. W.E. Deming, Out of the Crisis, MIT Center for Advanced Engineering Study, Cambridge, MA, 1982.
9. Urquhart J. Can delivery systems deliver value in the new pharmaceutical marketplace? Br. J. Clin. Pharmacol. 44:1997;413-419.
10. L.L. Brunton, Agents for control of gastric acidity and treatment of peptic ulcers, in: J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Gilman (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn., McGraw-Hill, New York, 1996, p. 908.
11. PRILOSEC (omeprazole) delayed-release capsules, Physicians' Desk Reference, 51st edn., Medical Economics Co., Montvale, NJ, 1997, pp. 516-519.
12. Guillebaud J. Any questions. Br. Med. J. 307:1993;617.
13. NORDETTE®-28 Tablets (levonorgestrel and ethinyl estradiol tablets), Physicians' Desk Reference, Medical Economics Co., Montvale, NJ, 1997, pp. 2866-2867.
14. Johnson B.F., Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am. J. Ther. 1:1994;260-264.
15. Vaur L., Dutrey-Dupagne C., Boussac J. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J. Cardiovasc. Pharmacol. 26:1995;127-131.
16. Leenen F.H.H., Fourney A., Notman G., Tanner J. Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br. J. Clin. Pharmacol. 41:1996;83-88.
17. Hernandez-Hernandez R., Armas de Hernandez M.J., Armas-Padilla M.C., Carvajal A.R., Guerrero-Pajuelo J. The effects of missing a dose of enalapril versus amlodipine on ambulatory blood pressure. Blood Press. Monitoring. 1:1996;1121-1126.
18. Anon, Long-term use of beta blockers: the need for sustained compliance, WHO Drug Inform. 4 (1990) 52-53.
19. Feinstein A.R., Spagnuolo M. Experimental reactivation of subsiding rheumatic fever. J. Clin. Invest. 40:1961;1891-1899.
20. Feinstein A.R., Spagnuolo M., Gill F.A. The rebound phenomenon in acute rheumatic fever: I. Incidence and significance. Yale J. Biol. Med. 33:1961;259-278.
21. Vanhove G.F., Schapiro J.M., Winters M.A., Merigan T.C., Blaschke T.F. Patient compliance and drug failure in protease inhibitor monotherapy. J. Am. Med. Assoc. 276:1996;1955-1956.
22. Weis S.E., Slocum P.C., Blais F.X., King B., Nunn M., Matney G.B., Gomez E., Foresman B.H. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N. Engl. J. Med. 330:1994;1179-1184.
23. McCann M.F., Potter L.S. Progestin-only oral contraception: a comprehensive review. Contraception. 50(Suppl 1):1994;S9-S195.
24. NORPLANT® System (levonorgestrel implants), Physicians' Desk Reference, Medical Economics Co., Montvale, NJ, 1997, pp. 2868-2873.
25. J.A. Oates, Antihypertensive agents and the drug therapy of hypertension, in: J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Gilman (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn., McGraw-Hill, New York, 1996, p. 791.
26. SER-AP-ES reserpine, USP, Physicians' Desk Reference, Medical Economics Co., Montvale, NJ, 1997, p. 867.
27. Veterans Administration Cooperative Study Group on Antihypertensive Agents, Effects of treatment on morbidity in hypertension, I: results in patients with diastolic blood pressures averaging 115 through 129 mmHg. J. Am. Med. Assoc. 202 (1967) 1028-1034.
28. Veterans Administration Cooperative Study Group on Antihypertensive Agents, Effects of treatment on morbidity in hypertension, II: results in patients with diastolic blood pressures averaging 90 through 114 mmHg. J. Am. Med. Assoc. 213 (1970) 1143-1171.
29. Meredith P.A. Therapeutic implications of drug 'holidays'. Eur. Heart J. 17(Suppl A):1996;21-24.
30. L.Z. Benet, S.S. Oie, J.B. Schwartz, Design and optimization of dosage regimens; pharmacokinetic data, in: J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Gilman (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn., McGraw-Hill, New York, 1996, p. 1729.
31. Kostis J.B., Davis B.R., Cutler J.et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. J. Am. Med. Assoc. 278:1997;212-216.
32. L.S. Potter, Oral contraceptive compliance and its role in the effectiveness of the method, in: J.A. Cramer, B. Spilker (Eds.), Compliance in Medical Practice and Clinical Trials, Raven Press, New York, 1991, pp. 195-207.
33. R. Temple, Dose-response and registration of new drugs, in: L. Lasagna, S. Erill, C.A. Naranjo (Eds.), Dose-response Relationships in Clinical Pharmacology, Elsevier, Amsterdam, 1989, pp. 145-167.
34. Fischl M.A., Parker C.B., Pettinelli C.et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 323:1990;1009-1014.
35. DeDoncker P., Van Lint J., Dockx P. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis. 56:1995;180-183.
36. Anon, Antifungals, Prescriber's Lett. 4 (1997) 8.
37. Pullar T., Kumar S., Tindall H., Feely M. Time to stop counting the tablets? Clin. Pharmacol. Ther. 46:1989;163-168.